2 unknown. 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Erempharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis Tobramycin - Cystic Fibrosis | Phase 1 / Phase 2 | Unknown | Erempharma | 36 | 2011-04-01 | 2011-04-18 |
| Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® Nebcinal Tobi, Tobi Nebcinal - Cystic Fibrosis | Not applicable | Unknown | Erempharma | 12 | 2010-02-01 | 2011-02-02 |
Cystic Fibrosis (2)
Tobramycin (1)
France (2)
Gabriel Bellon (1) · Isabelle Durieu, Pr (1)